Matthew Winton Inozyme Pharma, Inc. (INZY) insider trading activity
Matthew Winton is COO of Inozyme Pharma, Inc.. Currently has a direct ownership of 3,188 shares of INZY, which is worth approximately $15,366. The most recent transaction as insider was on Mar 28, 2024, when has been sold 3,188 shares (Common Stock) at a price of $3.33 per share, resulting in proceeds of $10,616. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).
Shares Held (Direct Ownership)
3.19K
n/a
3M change
n/a
12M change
Total Value Held
$15,366
MW
Matthew Winton
COO
Boston, MA